VETORYL Capsules offers a full range of sizes from 5 mg up to 120 mg, so you don't have to rely on
compounders to provide the dose that's right for the patient, regardless of how small or how large.
VETORYL Capsules are the only FDA veterinary-approved treatment for pituitary-dependent and adrenal-
dependent hyperadrenocorticism in dogs (Cushing's syndrome). They contain the active ingredient trilostane,
which blocks the excessive production of cortisol.
866-933-2472 | www.dechra-us.com | support@dechra.com
24 Hour Technical Support:
NADA 141-291, Approved by FDA CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian.
1
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm049823.htm
Vetoryl is a registered trademark of Dechra Limited. Dechra is a registered trademark of Dechra Pharmaceuticals PLC. ©2015, Dechra Ltd
As with all drugs, side effects may occur. In fi eld studies and post-approval experience, the most common side effects reported were: anorexia,
lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated BUN, decreased
Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insuffi ciency. In some cases, death has been reported as an
outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal disease,
or in pregnant dogs. Refer to the prescribing information for complete details or visit www.Dechra-US.com.
A Strength for Every Dog
AVAILABLE IN 5 MG, 10 MG, 30 MG,
60 MG AND 120 MG CAPSULES
• 2 Separate Modules – Learn at your own pace
• Free – Just sign up or use your existing Dechra login
• RACE Approved
www.dechra-us.com/CE
Come learn how to diagnose and treat
Cushing's disease in Dechra Academy